Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 50Leukemia, Myeloid, Chronic-Phase 32Leukemia 28Leukemia, Myeloid, Acute 18Breast Neoplasms 18Recurrence 15Prostatic Neoplasms 14Leukemia, Lymphocytic, Chronic, B-Cell 13Neoplasm Metastasis 12Blast Crisis 12Multiple Myeloma 11Carcinoma, Non-Small-Cell Lung 11Burkitt Lymphoma 11Pancreatic Neoplasms 10Neoplasms 9Leukemia, Myeloid, Accelerated Phase 9Lung Neoplasms 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 7Glioblastoma 7Melanoma 6Lymphoma 6Glioma 6Rectal Neoplasms 5Philadelphia Chromosome 5Ovarian Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Large B-Cell, Diffuse 5Hematologic Neoplasms 5

Interventions

masitinib 4Imatinib Mesylate 3midostaurin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Transplantation 1Tacrolimus 1Stem Cell Transplantation 1Sodium Chloride 1Single-Cell Gene Expression Analysis 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Injections 1Hydroxychloroquine 1Dasatinib 1Cyclophosphamide 1Cromolyn Sodium 1Cladribine 1Busulfan 1BNT162 Vaccine 1AK002 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mastocytosis × Dasatinib × Clear all
NCT00255346 2025-12-30

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡